COR Earnings

COR reported its earnings on 2026-02-04, showcasing a revenue of 85.93B against an estimate of 85.88B, resulting in a 0.06% surprise. The EPS was 4.08, surpassing the expected 4.07 by 0.25%. The stock experienced a -8.79% price change on the earnings day and a 0.42% change over the next five days, reflecting market reactions to the results.

Following COR's earnings announcement on 2026-02-04, the stock price moved by -8.79% on the day of the release. Over the subsequent five days, it saw a 0.42% change. Historically, COR's stock price tends to shift by an average of -1.45% in the 10 days leading up to earnings and 1.24% in the 10 days following, providing insight into potential market.

For 2026/Q2, analysts estimate COR's annual revenue to reach 79.84B, while the EPS is projected at 4.90. These estimates reflect recent revisions, with revenue estimates revised upward by 0.06% and EPS estimates revised upward by 0.03% over the past three months, indicating analyst expectation in the company's performance.

The correlation between COR's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock's fundamentals. Over the past three months, revenue estimates for FY2026 were revised upward by 0.06%, while EPS estimates moved revised upward by 0.03%. This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, COR's stock price typically moves by -1.45% in the 10 days before its earnings and 1.24% in the 10 days after. For the upcoming 2026/Q2 earnings, analysts expect an EPS of 4.90 and revenue of 79.84B.

The earnings call reflects a positive outlook with increased guidance for operating income and EPS, strategic partnerships, and strong specialty sales. Despite some headwinds like the oncology customer loss and interest expenses, the company anticipates growth driven by the OneOncology acquisition and strategic investments. The Q&A section reassures that challenges like the International segment timing issue won't affect full-year guidance. Additionally, a 9% dividend increase aligns with EPS growth guidance, further supporting a positive sentiment.